EDB-FN靶向探针用于甲状腺癌的手术导航、放射性核素显像与治疗
本研究基于纤连蛋白额外结构域B(EDB-FN)靶点,经丙氨酸扫描优化获得高亲和力肽EDBp(AVRTSAD),并构建Cy5-EDBp、[18F]-EDBp和[177Lu]-EDBp三种探针,分别在甲状腺癌荷瘤小鼠中用于荧光成像、PET显像和放疗,并在两例甲状腺癌患者中评估[18F]-EDBp。EDBp与EDB片段蛋白结合亲和力Kd=14.4±1.4 nM(n=3),约为ZD2(Kd=4839.7±361.7 nM,n=3)的336倍。
要点
- EDBp与EDB片段蛋白结合亲和力Kd=14.4±1.4 nM(n=3),约为ZD2的336倍。
- [18F]-EDBp PET显像清晰勾勒甲状腺癌肿瘤,注射后1小时肿瘤摄取高达16.43±1.008%ID/g(n=6)。
- [177Lu]-EDBp放疗抑制肿瘤生长并延长荷瘤小鼠生存期。
核心结论
- Cy5-EDBp、[18F]-EDBp和[177Lu]-EDBp分别是甲状腺癌手术导航、放射性核素显像和放射性核素治疗的有前景候选探针。
研究设计与样本
- 基于既往鉴定的EDB-FN靶向肽ZD2,采用丙氨酸扫描策略优化获得EDB-FN靶向肽EDBp。
- 构建三种EDBp基探针Cy5-EDBp、[18F]-EDBp和[177Lu]-EDBp,分别在甲状腺癌荷瘤小鼠中用于荧光成像、PET显像和放疗。
- [18F]-EDBp另在两例甲状腺癌患者中进行了评估。
主要发现
- EDBp与EDB片段蛋白结合亲和力Kd=14.4±1.4 nM(n=3),约为ZD2(Kd=4839.7±361.7 nM,n=3)的336倍。
- Cy5-EDBp荧光成像有助于甲状腺癌肿瘤的完整切除。
- [18F]-EDBp PET显像清晰勾勒甲状腺癌肿瘤,注射后1小时肿瘤摄取高,为16.43±1.008%ID/g(n=6)。
- [177Lu]-EDBp放疗抑制甲状腺癌荷瘤小鼠肿瘤生长并延长生存期,各治疗组生存时间:生理盐水组 vs. EDBp组 vs. ABRAXANE组 vs. [177Lu]-EDBp组 = 8.00天 vs. 8.00天 vs. 11.67天 vs. 22.33天(***P < 0.001)。
- [18F]-EDBp首次人体评估显示其具有特异性靶向特性(SUVmax值为3.6)和安全性。
关键数值与推荐
- EDBp与EDB片段蛋白结合亲和力Kd=14.4±1.4 nM(n=3),ZD2为Kd=4839.7±361.7 nM(n=3),EDBp约为ZD2的336倍。
- [18F]-EDBp在荷瘤小鼠注射后1小时肿瘤摄取为16.43±1.008%ID/g(n=6)。
- [177Lu]-EDBp组荷瘤小鼠生存时间为22.33天,生理盐水组为8.00天,EDBp组为8.00天,ABRAXANE组为11.67天(***P < 0.001)。
- [18F]-EDBp首次人体评估中SUVmax值为3.6。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Extradomain B of fibronectin (EDB-FN) is a promising diagnostic and therapeutic biomarker for thyroid cancer (TC). Here, we identified a high-affinity EDB-FN targeted peptide named EDBp (AVRTSAD) and developed three EDBp-based probes, Cy5-PEG4-EDBp(Cy5-EDBp), [18F]-NOTA-PEG4-EDBp([18F]-EDBp), and [177Lu]-DOTA-PEG4-EDBp ([177Lu]-EDBp), for the surgical navigation, radionuclide imaging, and therapy of TC. METHODS: Based on the previously identified EDB-FN targeted peptide ZD2, the optimized EDB-FN targeted peptide EDBp was identified by using the alanine scan strategy. Three EDBp-based probes, Cy5-EDBp, [18F]-EDBp, and [177Lu]-EDBp, were developed for fluorescence imaging, positron emission tomography (PET) imaging, and radiotherapy in TC tumor-bearing mice, respectively. Additionally, [18F]-EDBp was evaluated in two TC patients. RESULTS: The binding affinity of EDBp to the EDB fragment protein (Kd = 14.4 ± 1.4 nM, n = 3) was approximately 336-fold greater than that of the ZD2 (Kd = 4839.7 ± 361.7 nM, n = 3). Fluorescence imaging with Cy5-EDBp facilitated the complete removal of TC tumors. [18F]-EDBp PET imaging clearly delineated TC tumors, with high tumor uptake (16.43 ± 1.008%ID/g, n = 6, at 1-h postinjection). Radiotherapy with [177Lu]-EDBp inhibited tumor growth and prolonged survival in TC tumor-bearing mice (survival time of different treatment groups: saline vs. EDBp vs. ABRAXANE vs. [177Lu]-EDBp = 8.00 d vs. 8.00 d vs. 11.67 d vs. 22.33 d, ***p < 0.001). Importantly, the first-in-human evaluation of [18F]-EDBp demonstrated that it had specific targeting properties (SUVmax value of 3.6) and safety. CONCLUSION: Cy5-EDBp, [18F]-EDBp, and [177Lu]-EDBp are promising candidates for the surgical navigation, radionuclide imaging, and radionuclide therapy of TC, respectively.
引用
- Li R, He H, Li X, et al. EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 36807768. doi:10.1007/s00259-023-06147-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。